Implementing Fragment-based drug design to tackle neglected infectious targets
About the project:
Trypanosomiasis is a neglected disease caused by Trypanosoma parasites. An essential membrane-bound protein that is required for the biogenesis of glycosomes in these parasites is Pex14. The N terminal domain of Pex14 is required for binding the glyocosomal targeting receptor Pex5, and this protein-protein interaction is crucial for trypanosomal metabolism as it transfers glycolytic enzymes from the cytosol to the glycosome. Specific inhibition of this Protein-Protein-Interface (PPI) has been established to be a promising route to target Trypanosomasis and this project focuses on developing new druggable inhibitors for this Protein-Protein Interface. A Fragment-based approach is implemented as fragments screening has proven to be an effective tool in finding novel hits to be starting points for subsequent lead development. Its success is derived from deploying low molecular weight compounds which enables fast screening of libraries relative to more complex ligands.
Engi Hassaan was born in Cairo, Egypt. She is a graduate of the German University in Cairo where she earned her bachelor’s degree in Pharmacy and Biotechnology in 2011. In 2014 she received her Masters in Science degree from the same university, with a thesis entitled ‘Mining ZINC Database to Discover Potential Phosphodiesterase 9 Inhibitors Using Structure Based Drug Design Approach’. Engi moved to Marburg, Germany where she is currently pursuing her PhD degree. Besides Germany, she has also lived in Hong Kong, USA, Syria, and Jordan.
Helmholtz Zentrum München (2 month), ETH Zürich (1 month)
List of publications:
List of posters:
18th Annual Drug Discovery Summit 2017, June 12/13, Berlin, Germany
List of presentations:
Institut für Pharmazeutische Chemie
Marbacher Weg 6